** GlaxoSmithKline's new inhaled lung drugs finallybuilding momentum in all-important U.S. market, with Breo weeklyprescriptions hitting 30,000 and Anoro/Incruse also improving,according to IMS data
** GSK insiders say more focused approach by U.S. salesforce helping, after earlier disappointing performance by newproducts that needed to offset decline of top-seller Advair
** Bank of America Merrill Lynch upgraded stock to "buy"from "neutral" on Dec. 9, citing returning growth and pipelineoptionality
(RM: ben.hirschler.thomsonreuters.com@reuters.net)